[CAS NO. 1047634-65-0] Uprosertib (GSK2141795)
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1047634-65-0]
Store
Catalog
SLK-S7492
Brand
Selleck
CAS
1047634-65-0
DESCRIPTION [1047634-65-0]
Overview
| MDL | MFCD28144686 |
|---|---|
| Molecular Weight | 429.25 |
| Molecular Formula | C18H16Cl2F2N4O2 |
| SMILES | O=C(C1=CC(C2=C(Cl)C=NN2C)=C(Cl)O1)N[C@@H](CC3=CC=C(F)C(F)=C3)CN |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Description
Uprosertib (GSK2141795, GSK795) is a selective, ATP-competitive, and orally bioavailable inhibitor with of 180 nM, 328 nM, and 38 nM for Akt 1, 2 and 3, respectively. Phase 2.
In vitro
Uprosertib inhibits multiple AKT substrate phosphorylation levels, including GSK3β, PRAS40, FOXO and Caspase 9 in both BT474 and LNCaP cells. Uprosertib preferentially inhibits the proliferation of human cancer cells lines with AKT pathway activation. In LNCaP, BT474, A3 and I9.2 cells lines, Uprosertib also causes cell cycle arrest. In both SKOV3 and PEO4 cells, Uprosertib causes growth-arrest as single agent, and enhances cisplatin-induced apoptosis.
In vivo
In mice bearing BT474 breast tumor xenografts, Uprosertib (100 mg/kg, p.o.) results 61% tumor growth inhibition. In mice bearing SKOV3 ovarian tumor xenografts, Uprosertib (30 mg/kg, p.o.) results 61% tumor growth inhibition.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.